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6-hydroxydopamine (6-OHDA) is a selective neurotoxin that is widely used to investigate cell death and protective strategies
in models of Parkinson’s disease. Here, we investigated the eﬀects of the endogenous cannabinoid, anandamide, on 6-OHDA-
induced toxicity in rat adrenal phaeochromocytoma PC12 cells. Morphological analysis and caspase-3 activity assay revealed
that anandamide inhibited 6-OHDA-induced apoptosis. The protection was not aﬀected by antagonists of either cannabinoid
receptors (CB1 or CB2) or the vanilloid receptor TRPV1. Anandamide-dependent protection was reduced by pretreatment with
LY294002 (inhibitor of phosphatidylinositol 3-kinase, PI3K) and unaﬀected by U0126 (inhibitor of extracellularly-regulated
kinase). Interestingly, phosphorylation of c-Jun-NH2-terminal kinase (JNK) in cells exposed to 6-OHDA was strongly reduced
by anandamide pre-treatment. Furthermore, 6-OHDA induced c-Jun activation and increased Bim expression, both of which
were inhibited by anandamide. Together, these data demonstrate antiapoptotic eﬀects of anandamide and also suggest a role for
activation of PI3K and inhibition of JNK signalling in anandamide-mediated protection against 6-OHDA.
1.Introduction
In recent years, the endogenous cannabinoid (endocannabi-
noid) system has emerged as a potential therapeutic target
for the treatment of Parkinson’s disease [1–5]. These studies
suggest that the potential therapeutic beneﬁts of cannabi-
noid drugs may include neuroprotection of nigrostriatal
dopaminergic neurons. This is of particular interest since
neuroprotective therapies for Parkinson’s disease are notably
lacking, and current therapies are generally dopamine-
enhancing strategies, that neither halt nor delay ongoing
neurodegeneration. Anandamide (also known as arachi-
donylethanolamide), was the ﬁrst endocannabinoid to be
discovered, is derived from arachidonic acid and found
principally in brain tissue [6]. Anandamide binds and
activates the cannabinoid receptors (CB1 and CB2) and also
the vanilloid receptor, TRPV1 [7, 8].
Mounting evidence supports a role for anandamide
in the modulation of cell fate, including cell death and
survival. Anandamide can protect neurons from toxic insults
such as glutamatergic excitotoxicity, nutrient deprivation,
hypoxia and ischemia [9–12]. These protective eﬀects of
anandamide have been reported to be mediated by CB1 and
CB2 cannabinoidreceptors,whereasactivationofTRPV1has
been suggested to mediate anandamide-induced apoptosis
in rat C6 glioma cells, human DAUDI leukemia cells, and
cervical carcinoma cell lines [13–15].
The present study was undertaken to examine the
ability of anandamide to protect PC12 cells against 6-
hydroxydopamine (6-OHDA) toxicity. 6-OHDA is a hydrox-
ylated analogue of dopamine that is commonly used in
model systems to mimic Parkinson’s disease [16, 17].
6-OHDA induces apoptosis of primary mesencephalic
dopaminergic neurons [18, 19], MN9D [20] and dopamin-
ergic cell lines including PC12 [17, 21, 22]. Apoptosis is
a highly regulated form of cell death that occurs under
physiological and pathological conditions. It is characterised
morphologically by cell shrinkage and nuclear condensa-
tion. These changes are mediated by activation of caspase
proteases, and in the case of 6-OHDA this occurs as2 International Journal of Cell Biology
a result of release of cytochrome c from the mitochondria
[22].
Here we examine the eﬀect of anandamide on 6-
OHDA-induced toxicity in PC12 cells. In particular, the
mechanism of anandamide action against 6-OHDA was
tested by examining the possible role of signalling pathways,
which are well known to be involved in regulation of cell fate,
including phoshpatidylinositol 3-kinase (PI3K)/Akt, mito-
gen activated protein kinase (MAPK)/extracellular signal-
regulated kinase1/2 (ERK1/2) and c-Jun-NH2-terminal
kinase (JNK)/c-Jun pathways.
2.ExperimentalProcedures
2.1. Materials. Rat phaeochromocytoma PC12 cells were
obtained from European Collection of Cell Cultures
(ECACC). All chemicals were supplied by Sigma–Aldrich
unless stated otherwise. Anandamide and SB366791 were
obtained from Tocris Bioscience. SR141716A and SR144528
were from NIMH Chemical Synthesis and Drug Supply Pro-
gram. U0126 and SP600125 were supplied by Calbiochem.
Rabbit polyclonal antibody against Bim was from StressGen
Biotechnologies. Mouse monoclonal antibody against p-
JNK, rabbit polyclonal anti-caspase-3 antibody and rabbit
monoclonal antibody against p-ERK1/2 were obtained from
Cell Signalling Technology. Mouse monoclonal antibody
against p-c-Jun was from Santa Cruz Biotechnology. Anti-
Actin rabbit polyclonal antibody was from Sigma-Aldrich.
Goat secondary antibodies conjugated to horseradish per-
oxidase were from Pierce. Ac-Asp-Glu-Val-Asp-a-(4-methyl-
coumaryl-7-amide) (DEVD-MCA) was from the Peptide
Institute,Osaka,Japan.Proteinmolecularweightmarkerwas
obtained from New England Biolabs.
2.2. Cell Culture and Treatments. Rat adrenal phaeochro-
mocytoma PC12 cells were cultured in DMEM supple-
mented with 10% horse serum, 5% fetal calf serum, 50
U/ml penicillin and 50μg/ml streptomycin, at 37
◦Ci na
humidiﬁed 5% CO2 atmosphere. For experiments, cells were
seeded at a density of 7 × 104 cells/cm2 in plates coated
with 10μg/ml poly-L-lysine. Cells were left overnight before
commencing experimental treatments. Stock solutions of 6-
OHDA were made freshly in sodium metabisulﬁte (1M)
prior to each experiment. Unless otherwise stated, PC12
cells were incubated with 25μM anandamide for 24 hours
followed by treatment with 100μM 6-OHDA for further 24
hours before analysis.
2.3. Cell Viability and Proliferation Assay. Cell survival
was determined by using colorimetric MTT (3-(4,5-
dimethylthiazolyl-2)-2,5-diphenyltetrazoliumbromide) tet-
razolium salt assay [23]. PC12 cells were plated into 96-
well plates at 1.7 × 104 cells/well in 100μlo fm e d i u m .
MTT tetrazolium salt was dissolved in Hank’s balanced salt
solution to concentration of 5mg/ml. After experimental
treatments,10μlofMTTwasaddedtotheculturefor3hours
at 37
◦C. To stop the reaction and solubilize the formazan
crystals 100μl of 20% SDS in 50% dimethyl formamide
was added and the absorbance was measured at 550nm by
a Wallac 1420 plate-reader with a reference wavelength of
650nm. Cell viability was expressed as percent of the control
culture.
2.4. DAPI Staining of Nuclei. Cells were washed in PBS
and ﬁxed with 3.7% paraformaldehyde for 10 minutes at
roomtemperature.Nucleiwerestainedwith4 -6-diamidino-
2-phenylindole (DAPI) and placed in mounting medium
(Vectashield, Vector, Burlingame, CA). 5μl aliquot of the
cell suspensions were applied to glass slides. Morphological
changes in chromatin of cells undergoing apoptosis were
analysed by ﬂuorescence microscopy (excitation 350nm and
emission at 460nm). Cells were scored by counting at least
3 0 0c e l l sf r o me a c hs a m p l e .
2.5. DEVDase Activity Assay. The activity of caspase-3-
like enzymes (DEVDases) was determined ﬂuorometri-
cally as reported previously [24] with some modiﬁca-
tions [22, 25]. Brieﬂy, cells were scraped and spun down
at 300 × ga t4 ◦C for 5 min. Pellets were washed
in ice-cold phosphate-buﬀered saline (PBS) and spun
down again at 20000 × g for 10 seconds. The pel-
lets were re-suspended in 25μl PBS and snap-frozen in
liquid nitrogen. 50μM of DEVDase-substrate (DEVD-
MCA) in reaction buﬀer (100mM N-2-hydroxyethyl-
piperazine-N-2-ethanesulphonic acid (HEPES) pH 7.5, 10%
sucrose, 0.1% 3-[(3-cholamidopropyl)-dimethylammonio]-
1-propanesulfonate (CHAPS), 5mM dithiothreitol (DTT),
10
−4% Nonidet-P-40) was added into lysates and the release
of free AMC was monitored at 37
◦C at 60 seconds intervals
over a 30 minute period using a Wallac Victor multilabel
counter (excitation 355nm, emission 460nm). Fluorescent
units were converted to nanomoles of AMC released using a
standard curve generated with free AMC and subsequently
related to protein concentration.
2.6. Preparation of Whole Cell Extracts. Following exper-
imental treatments cells were scraped from the culture
ﬂasks and centrifuged at 150 × gf o r5m i n u t e sa t4 ◦C.
After washing in PBS cells were lysed using whole cell lysis
buﬀer (20mM HEPES pH 7.5, 350mM NaCl, 1mM MgCl2,
0.5mM EDTA, 0.1mM EGTA, 1% Nonidet P-40, 0.5mM
DTT, 0.1% phenylmethylsulphonyl ﬂuoride (PMSF), 1%
aprotinin, 5mM NaF, and 1mM Na3VO4). Cellular debris
was spun down at 20,000 × g for 1 minute and supernatant
was taken to determine the protein content using Bradford
reagent with bovine serum albumin (BSA) as the standard.
2.7. Western Blotting. 40μg of proteins were denatured using
Laemmli’s sample buﬀer (62mM Tris-HCl, pH 6.8, 2%
sodium dodecyl sulphate (SDS), 5% β-mercaptoethanol, 4%
glycerol, 1mM PMSF, 0.01% bromophenol blue) and boiled
at 95
◦C for 5 minutes. Proteins were separated by 10%–
15% SDS-PAGE and electrophoretically transferred onto
nitrocellulose membranes. Membranes were blocked for 1
hour in PBS containing 0.05% Tween 20 and 5% (w/v)International Journal of Cell Biology 3
non-fat dried milk. Membranes were probed with anti-
bodies (1 : 1000) overnight at 4◦C followed by appropriate
horseradish peroxidise-conjugated goat secondary antibody
at 1 : 10,000 (or 1 : 2,000 for detection of caspase-3) for 2
hours at room temperature. Protein bands were visualized
using Supersignal West pico system (Pierce).
2.8. Statistical Analysis. V a l u e sa r ee x p r e s s e da sm e a n s±
SEM of 3 separate experiments unless otherwise indicated.
Statistical analysis was performed using repeated-measures
ANOVA followed by Bonferroni multiple comparisons post
hoc test, for which levels of P<. 05 were considered to be
signiﬁcant.
3. Results
3.1. Anandamide Pre-Treatment Protects PC12 Cells against
6-OHDA Toxicity. We have previously shown that 6-OHDA
causes a concentration-dependent induction of apoptosis
in PC12 cells [22]. In order to examine the eﬀect of
anandamide against 6-OHDA, PC12 cells were incubated
with 25μM anandamide for 24 hour followed by exposure
to 100μM 6-OHDA for a further 24 hours. Visualisation
of nuclear morphology by DAPI staining demonstrated that
pre-treatment of PC12 cells with anandamide inhibited 6-
OHDA-induced apoptosis (Figure 1(a)). The level of cell
death due to 6-OHDA with and without prior anandamide
treatment was quantiﬁed and expressed as a percentage
of the total number of cells. Anandamide alleviated the
morphological manifestation of celldamageand reducedcell
death from 19.2 ± 2.8% to 4.7 ± 4.6% (Figure 1(b)).
Next the eﬀect of anandamide on caspase 3-like activity
(DEVD-MCA cleavage activity) was examined. PC12 cells
were treated with 0–50μM anandamide for 24 hours prior
to treatment with 6-OHDA for a further 24 hours. Anan-
damideeﬀectivelyinhibitedDEVD-MCA-cleavageactivityin
a concentration-dependent manner, causing approximately
50% inhibition at 10μM anandamide (Figure 1(c)). This
was accompanied by a reduction in the processing of pro-
caspase-3 into its active 17kDa form, as detected by Western
blotting (Figure 1(d)). These data indicate that anandamide
can protect against 6-OHDA-induced apoptosis at the level
of, or upstream of, caspase-3 activation.
3.2. Anandamide-Mediated Protection Is Cannabinoid and
Vanilloid Receptor-Independent. In order to determine
whethertheeﬀectofanandamideisreceptor-mediated,PC12
cells, which express the CB1 receptor ([26], and our own
data not shown) were incubated with selective CB1 or CB2
receptor antagonists, SR141716A or SR144528, respectively,
prior to treatment with 25μM anandamide and 6-OHDA.
The receptor antagonists did not inhibit the protective
eﬀects of anandamide, indicating that neither CB1 nor CB2
receptors are involved in anandamide protection against
6-OHDA toxicity (Figures 2(a) and 2(b)). Application of the
antagonists at excess concentrations (25μM for SR141716A;
20μM for SR144528) also did not reverse the protection
(Figures 2(a) and 2(b)). Since anandamide also has activity
at the TRPV1 vanilloid receptor [8], and since this receptor
is expressed in PC12 cells [26, 27], the eﬀect of a TRPV1
selective antagonist, SB366791, on anandamide protection
was examined. SB366791 had no eﬀect on the protective
abilities of anandamide against 6-OHDA-induced caspase
activity (Figure 2(c)). In addition, none of the antagonists
had any eﬀect on 6-OHDA-induced DEVDase activity in the
absence of anandamide. Cannabinoids, particularly those
possessing a phenolic ring, are known to exert receptor-
independent eﬀects on cells and the neuroprotective eﬀects
have been suggested to be related to the potent antioxidant
properties of cannabinoids [28]. Since 6-OHDA-induced
cell death can be mediated by oxidative stress [17, 20, 29],
the eﬀect of anandamide on H2O2-induced cell death was
examined. Anandamide did not prevent cell death due to
H2O2 as determined by MTT survival assay (Figure 3).
This suggests that anandamide-mediated protection against
6-OHDA is not a consequence of its antioxidant ability.
3.3. Involvement of PI3K and ERK1/2 Signalling Pathways
in the Prosurvival Action of Anandamide. Cannabinoid-
dependent eﬀects have been associated with several sig-
nal transduction pathways including activation of phos-
phatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated
protein kinase (MAPK) signalling pathways, both of which
are linked to prosurvival signalling [30–32]. To gain insight
into the molecular mechanism leading to cell survival, we
studied the role of these signalling pathways in anandamide
protection. Inhibition of PI3K with 40μM LY294002 was
found to exacerbate 6-OHDA toxicity (Figure 4(a)). Pre-
treatment with LY294002 reversed anandamide-mediated
protection, although not to the level in the absence of
anandamide, probably due to the eﬀect of LY294002 in
enhancing 6-OHDA-induced toxicity.
To assess a possible role of MEK/ERK signalling in
anandamide-mediated protection, we used Western blotting
to examine the eﬀect of anandamide on the phosphorylation
status of ERK1/2. Treatment of PC12 cells with 25μM
anandamide resulted in a transient increase in ERK1/2
phosphorylation at 6 hours that returned to basal levels
by 24 hours (Figure 4(b)). Pharmacological inhibition of
ERK activation by 10μM U0126 partially reversed the
eﬀect of anandamide on DEVDase activity, but without
statistical signiﬁcance (Figure 4(c)). This suggests that the
increase in ERK1/2 phosphorylation does not make a major
contribution to anandamide-mediated protection.
3.4. Anandamide Inhibits JNK Activation Induced by 6-
OHDA. The stress kinase JNK has been reported to medi-
ate 6-OHDA-induced cell death [20, 33]. Therefore, we
examined the eﬀect of anandamide on JNK activation by
examining the phosphorylation status of JNK1 and JNK2.
Treatment of PC12 cells with 100μM 6-OHDA evoked
a time-dependent increase in JNK1 phosphorylation with
maximal activation after 6 hours (Figure 5(a)). There was
a smaller increase in JNK2 phosphorylation that followed
the same time course. Prior treatment with anandamide
resulted in a marked inhibition of JNK1 phosphorylation4 International Journal of Cell Biology
(A) (B)
(C) (D)
(a)
0
10
20
30
−
−
+
−
−
+
+
+
AEA
6-OHDA
N
u
c
l
e
a
r
c
o
n
d
e
n
s
a
t
i
o
n
(
%
)
(b)
0
10
20
30
40
50
60
70
80
90
100
−8 −7 −6 −5 −4
D
E
V
D
a
s
e
a
c
t
i
v
i
t
y
(
%
o
f
6
-
O
H
D
A
a
l
o
n
e
)
log [AEA]
6-OHDA
Untreated
(c)
42
17
32 Pro-caspase-3
Cleaved caspase-3
Actin
(kDa)
−
−
+
−
−
+
+
+
100 μM 6-OHDA
25 μMA E A
(d)
Figure 1: Inhibition of 6-OHDA-induced apoptosis by anandamide. (a) PC12 cells were treated with 25μM anandamide for 24 hours and
then exposed to 100μM 6-OHDA for a further 24 hours. Cytocentrifuge preparations of control and treated cells were stained with DAPI
to visualise nuclear changes. The apoptotic cells with condensed and fragmented nuclei are indicated by arrows. Cells were (a) untreated,
(b) exposed to 6-OHDA, (c) treated with AEA only or (d) treated with AEA and then exposed to 6-OHDA. (b) The level of cell death due
to 6-OHDA with and without prior anandamide treatment was quantiﬁed and expressed as a percentage of the total number of cells. The
results shown are the average of two separate experiments ± range. (c) PC12 cells were treated with a range of concentrations of anandamide
(0–50μM )f o r2 4h o u r sp r i o rt oe x p o s u r et o1 0 0μM 6-OHDA for a further 24 hours. DEVDase activity was measured in whole cell extracts.
Values represent the mean ± SEM of four independent determinations. (d) PC12 cells were exposed to 25μM anandamide for 24 hours
followed by treatment with 100μM 6-OHDA for further 24 hours. Pro-caspase-3 processing was visualized by Western blotting. Actin was
used as a loading control. The data are representative of two independent experiments.
(Figure 5(a)). These ﬁndings suggest that suppression of
JNK activation may play an important role in anandamide-
dependent protection against 6-OHDA and are in agreement
with other studies showing that inhibition of JNK activity
protects PC12 cells against 6-OHDA-induced apoptosis [20,
33–37].
Many JNK targets are implicated in cell death, including
c-Jun and the BH3-only protein Bim [38]. Therefore, the
eﬀect of anandamide on these JNK targets was examined. 6-
OHDA caused an increase in c-Jun phosphorylation which
was reduced by anandamide pre-treatment (Figure 5(b)).
BimEL, a pro-apoptotic member of the Bcl-2 family, is
also a target of JNK. Treatment of cells with 6-OHDA
caused a marked increase in BimEL expression by 12
hours (Figure 5(b)). Three BimEL bands were observed
with the higher molecular weight forms probably reﬂectingInternational Journal of Cell Biology 5
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Figure 2: Anandamide-mediated prosurvival eﬀect is cannabinoid and vanilloid receptor-independent. PC12 cells were treated with 25μM
anandamide for 24 hours, with or without selective receptor antagonists, and then exposed to 100μM 6-OHDA for a further 24 hours.
Eﬀector caspase activity was measured by DEVDase assay in whole cell extracts. (a) Indicated concentrations of CB1 receptor antagonist
SR141716A were added 1 hours prior to incubation with anandamide. Values represent the mean ± SEM of 3 independent determinations,
∗P<. 001. (b) Indicated concentrations of CB2 receptor antagonist SR144528 were added 1 hour prior to incubation with anandamide.
Values represent the mean ± SEM of 3 independent determinations,
∗P<. 001. (c) The TRPV1 receptor antagonist SB366791 at 10μMw a s
added 1 hour prior to incubation with anandamide. The data shown are average of two separate experiments ± range.
phosphorylated species, since this protein is known to
be regulated by phosphorylation [39, 40]. In fact, we
have previously shown that these upper bands represent
phosphorylated BimEL, since they disappear upon treatment
of whole cell lysates with phosphatase [32]. Pre-treatment
of the cells with anandamide did not appear to aﬀect the
time course or level of induction of BimEL (Figure 5(b)).
However, there was a reduction in the higher molecular
weight band for BimEL and an increase in the intensity of the
lower molecular weight band at 24 hours of 6-OHDA with
AEA treatment (Figure 5(b)). These data suggest that there
is an anandamide-induced reduction in phosphorylation of
BimEL, possibly due to JNK inhibition.
In order to conﬁrm a role for JNK activation in 6-
OHDA toxicity, cells were pre-treated with the JNK inhibitor
SP600125(4μM).Thisinhibitorreducedphosphorylationof
c-Jun by 6-OHDA and also caused a delay and a reduction in
cleavage of caspase-3 to its active p17 fragment (Figure 5(c)).
In the same experiment, 25μM anandamide had caused
complete inhibition of caspase-3 cleavage while inhibiting c-
Jun phosphorylation, but to a lesser extent than SP600125.
4. Discussion
Hereweprovidetheﬁrstevidencefordirectprotectiveeﬀects
of anandamide against 6-OHDA toxicity. Anandamide6 International Journal of Cell Biology
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Figure 3:EﬀectofanandamideonH2O2 inducedoxidativestressin
PC12 cells. Cells were treated with 25μM anandamide for 24 hours,
followed by treatment with the indicated concentrations of H2O2
for another 24 hours. Cell viability was assessed by the MTT assay.
The data shown are average of two separate experiments ± range.
blocks 6-OHDA-induced apoptosis in a concentration-
dependentmanner.Thisprotectionwasupstreamofcaspase-
3 activation since there was inhibition of DEVDase activity
and a reduction in processing of pro-caspase-3. We were
unable to demonstrate a role for CB1,C B 2 or TRPV1
in anandamide protection. Nor did it involve ERK1/2
prosurvival signalling. However, a partial role for PI3K
activation and suppression of JNK signalling were demon-
strated. Cannabinoids have been shown to both induce
and inhibit induction of cell death, (reviewed by [41]).
Anandamide itself has been reported to be toxic [26]o r
nontoxic [42] to PC12 cells. In our study, anandamide, at
the concentrations used, was not toxic even up to 48 hours
of incubation (data not shown). Cannabinoid drugs have
been shown by others to be protective in a variety of models
of neurodegeneration [9, 41, 43], including neuronal cell
death in models of Parkinson’s disease [28]. For example, the
non-selective synthetic cannabinoid receptor agonist HU210
was found to protect cerebellar granule neurons against 6-
hydroxydopamine toxicity [28]. Furthermore, an in vivo
study demonstrated that the plant-derived cannabinoids Δ9-
THC and cannabidiol protect the rat nigrostriatal dopamin-
ergic pathway from a medial forebrain bundle injection
of the catecholamine neurotoxin 6-hydroxydopamine [28].
Althoughthatinvivostudydidnotincludedirectassessment
of neuroprotection, the ability of Δ9-THC or cannabidiol
to ameliorate the eﬀects of the 6-OHDA lesion on striatal
dopamine concentration and tyrosine hydroxylase activity
were shown. Our current data with anandamide support
these earlier ﬁndings.
A possible role of metabolites of anandamide in the
regulation of PC12 cell fate cannot be ruled out. Anan-
damide is enzymatically hydrolysed to ethanolamine and
arachidonic acid [44]. In fact, this degradation has been
shown to be necessary for its prosurvival eﬀects in murine
neuroblastoma cells where anandamide protective activity
against serum deprivation was not mediated via CB1/CB2 or
TRPV1 receptors and required a breakdown of anandamide
to ethanolamine [9].
It has been reported that induction of oxidative stress is
involved in 6-OHDA-induced toxicity and antioxidants can
protect against hydrogen peroxide and superoxide anion-
mediated cell death [20, 33–37, 45–47]. To our knowledge,
anandamide has not been reported to possess antioxidant
activity. We did not observe anandamide-mediated protec-
tion of PC12 cells against H2O2-induced death, suggesting
that anandamide does not inhibit oxidative stress due to
6 - O H D A .H o w e v e r ,H 2O2 is not the only product of 6-
OHDA auto-oxidation. In addition, superoxide anions and
p-quinone, may contribute to reactive oxygen species (ROS)
production [48–50] and may be inhibited by anandamide,
thus blocking JNK activation and phosphorylation of its
downstream targets.
Cannabinoids have been shown to activate PI3K/Akt
and MEK/ERK signalling pathways [51, 52]. While our
results obtained with pharmacological inhibitors did not
support a role for MEK/ERK signalling in anandamide
protection against 6-hydroxydopamine, they did support
an involvement of PI3K/Akt prosurvival signalling, since
the PI3K selective inhibitor LY294002 reversed anandamide
protection against 6-OHDA. In addition, the present data
also support a possible role for inhibition of JNK activation
in anandamide protection, since anandamide reduced 6-
OHDA-induced JNK phosphorylation and JNK-dependent
pro-apoptotic signalling, namely phosphorylation of c-Jun
a n dp o s s i b l yo fB i m EL.
JNKs are members of the mitogen-activated protein
kinase(MAPK)pathwaythatisactivatedinresponsetomany
extracellular stimuli and diﬀerent forms of environmental
stress[53].Ourﬁndingsareingeneralagreementwithrecent
reportsshowingthat6-OHDAinducesJNKphosphorylation
[36, 54] and that JNK activation mediates apoptosis induced
by 6-OHDA in PC12 cells [45, 47, 54]. Furthermore, a
number of studies showing protection by various agents
against 6-OHDA neurotoxicity also show a concomitant
suppression of JNK activation [20, 33–37]. We observed
a large 6-OHDA-induced increase in phosphorylation of
JNK1, and a minor increase in levels of phosphorylated
JNK2at3–6hours,whichareaccompaniedbyaconcomitant
increaseinphospho-c-Junandadelayedincreaseinthelevels
ofBimEL.Furthermore,theJNKinhibitorSP600125causeda
partial reduction in caspase-3 cleavage due to 6-OHDA. This
wasincontrasttocompleteinhibitionbyanandamide.These
ﬁndings are in agreement with a previous report showing
that SP600125 partially protects against 6-OHDA toxicity in
PC12 cells [47]. Taken together, these data suggest a partial
contribution of JNK signalling in the toxicity of 6-OHDA,
and that anandamide may mediate some of its protective
eﬀect through suppression of this pathway.
JNK promotes apoptosis in a number of ways. Through
phosphorylation and activation of c-Jun it stimulates the
transcription of c-Jun target genes, including Bim [38].
In addition, JNK phosphorylates certain members of the
Bcl-2 protein family, associated with the mitochondrialInternational Journal of Cell Biology 7
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Figure 4: Role of PI3K and MAPK signalling in anandamide-mediated protection against 6-OHDA toxicity. (a) PC12 cells were pre-treated
with 40μM LY294002 for 1 hours prior to addition of 25μM anandamide for 24 hours followed by treatment with 100μM6 - O H D Af o ra
further 24 hours. Values represent the mean ± SEM of 4 independent experiments.
∗P<. 005,P† <. 001. (b) PC12 cells were treated with
25μM anandamide for 0–24 hours. The phosphorylation state of ERK1/2 was analysed by Western blotting. Actin protein levels were also
analysed as a loading control. The results are representative of two separate experiments. (c) 10μM U0126, the MAPK pathway inhibitor
was added 1 hour prior to incubation of PC12 cells with 25μM anandamide for 24 hours and with 100μM 6-OHDA for a further 24 hours.
Values xrepresent mean ± SEM of three independent determinations. P† <. 001,
∗P<. 01.
apoptoticpathway,includingBimEL,Bmf,andBc l-2[38,53].
For example, BimEL levels and function are regulated by
phosphorylation by ERK, JNK and possibly Akt [40, 55].
Phosphorylation of BimEL at Ser65 by active JNK potentiates
its pro-apoptotic activity [56]. These data support an
attractive hypothesis that anandamide protects against 6-
OHDA at the level of, or upstream of, JNK activation.
This inhibition of JNK by anandamide thus prevents the
activation of downstream apoptotic pathways, including
activation of c-Jun and possibly phosphorylation of BimEL.
However, since the level of cytoprotection by anandamide
was far greater than that due to SP600125, despite similar
JNK inhibition, it strongly suggests that anandamide utilises
additional mechanisms to inhibit 6-OHDA toxicity.
It should be considered that in contrast to the data sup-
porting endocannabinoid-mediated JNK inhibition, there
are data reported by others [57–59] indicating that cannabi-
noids induce JNK activation, an eﬀect that precedes apop-
totic events including caspase-3 activation and DNA frag-
mentation. Thus, the neuroprotective and neurotoxic eﬀects8 International Journal of Cell Biology
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Figure 5: Anandamide partially protects against 6-OHDA-mediated apoptosis through inactivation of JNK signalling pathway. PC12 cells
were treated with 25μMo r5 0μM anandamide for 24 hours and then exposed to 100μM 6-OHDA for indicated periods of time. (a) The
phosphorylation state of JNK1/2 was analysed by Western blotting. Actin protein levels were also analysed as a loading control. (b) The
phosphorylation state of c-Jun and Bim isoforms were analysed by Western blotting. Actin protein levels were also analysed as a loading
control. Blots shown are representative of three independent experiments. (c) Where indicated, cells were exposed to 4μM SP600125 for 1
hour or 25μMA E Af o r2 4h o u rp r i o rt ot r e a t m e n tw i t h1 0 0μM 6-OHDA for further 24 hour. Phosphorylation of c-Jun and the processing
of caspase-3 to the active 17kDa fragment subunit were analysed by Western blotting. The levels of actin expression were also determined
for loading control. The data shown are representative of two separate experiments.
of cannabinoids are likely to depend on a variety of factors,
including toxic insults, doses and nature of cannabinoids
(e.g., endocannabinoids versus phytocannabinoids), times of
exposure and cell type [60, 61].
Here, for the ﬁrst time we demonstrate that anandamide
protects PC12 cells against 6-OHDA-induced apoptosis.
These data and those of other studies may suggest potential
therapeutic beneﬁts of elevating anandamide and possibly
other endocannabinoids in preventing the degeneration of
nigrostriatal dopaminergic neurons in Parkinson’s disease.
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